Skip to main content
Porton Pharma Solutions Ltd. logo

Porton Pharma Solutions Ltd. — Investor Relations & Filings

Ticker · 300363 ISIN · CNE100001S57 LEI · 300300IQTJFHA0YRXE68 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,163 across all filing types
Latest filing 2023-11-10 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300363

About Porton Pharma Solutions Ltd.

https://www.porton.cn

Porton Pharma Solutions Ltd. is a global contract development and manufacturing organization (CDMO) providing end-to-end solutions for the pharmaceutical and biotechnology sectors. The company specializes in the development and manufacturing of small molecule APIs, intermediates, and drug products, while expanding its capabilities into biologics and cell and gene therapies. Its service portfolio encompasses process research and development, analytical services, pilot-scale production, and large-scale commercial manufacturing. Porton operates a network of R&D centers and manufacturing facilities designed to meet international regulatory standards, including those of the FDA and EMA. By leveraging an integrated technology platform, the company supports clients throughout the entire drug lifecycle, from preclinical development to commercialization, focusing on operational excellence and supply chain security.

Recent filings

Filing Released Lang Actions
对外担保管理制度（2023年11月）
Governance Information Classification · 95% confidence The document is titled as a management system for external guarantees by Chongqing Boteng Pharmaceutical Technology Co., Ltd., revised in November 2023. It details internal policies, procedures, responsibilities, and disclosure requirements related to the company's external guarantees. There is no indication that this is a financial report, audit report, earnings release, or any form of regulatory filing. Instead, it is a governance document outlining internal rules and controls regarding external guarantees. Therefore, it fits best under Governance Information (CGR). The document length (5844 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2023-11-10 Chinese
关联交易决策制度（2023年11月）
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '关联交易决策制度' (Related Party Transaction Decision System) issued by 重庆博腾制药科技股份有限公司. It outlines the principles, definitions, decision-making procedures, disclosure requirements, and governance related to related party transactions. There is no indication that this is a financial report, earnings release, or regulatory announcement. It is a governance-related document detailing internal rules and procedures for related party transactions, which fits the definition of Governance Information (CGR). The document length (6679 characters) and content confirm it is a substantive policy document, not a brief announcement or certification.
2023-11-10 Chinese
公司章程（2023年11月）
Governance Information Classification · 100% confidence The document is titled as the "公司章程" (Company Articles of Association) for 重庆博腾制药科技股份有限公司, dated November 2023. It contains detailed provisions about the company's organizational structure, shareholder rights, board of directors, share issuance, share transfer, shareholder meetings, and other governance matters. It references relevant laws such as the Company Law and Securities Law of China. The content is a comprehensive governance document outlining internal rules and procedures rather than a financial report, announcement, or meeting material. It is not an Annual Report, Interim Report, Earnings Release, nor a voting result announcement. It is not a proxy statement or remuneration report. It is a governance document detailing the company's internal rules and board structure. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the actual governance document, not just an announcement or summary.
2023-11-10 Chinese
独立董事工作制度（2023年11月）
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and contains detailed governance rules and procedures related to independent directors of the company 重庆博腾制药科技股份有限公司. It includes sections on the general principles, conditions for independent directors, nomination and election processes, duties and powers, work guarantees, and other governance-related provisions. There is no financial data, earnings information, or audit results. The content is focused on governance structure and internal rules regarding independent directors, which aligns with governance information filings. The document length is 8598 characters, indicating it is a full policy document rather than a brief announcement or certification. Therefore, the appropriate classification is Governance Information (CGR).
2023-11-10 Chinese
关于召开2023年第五次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2023 fifth extraordinary general meeting of shareholders for Chongqing Porton Pharmaceutical Technology Co., Ltd. It includes information about the meeting date, agenda items, voting procedures, registration details, and attachments such as proxy forms and voting instructions. There is no financial data or report content, but rather an announcement and procedural information related to a shareholders' meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2023-11-10 Chinese
独立董事专门会议工作制度（2023年11月）
Governance Information Classification · 95% confidence The document is titled '独立董事专门会议工作制度' which translates to 'Independent Directors Special Meeting Work System'. It outlines the rules and procedures for independent directors' meetings within the company, including meeting frequency, notification, voting, confidentiality, and responsibilities. It references company governance laws and internal company rules but does not contain financial data, audit results, or any financial performance information. It is a governance-related document detailing internal rules and procedures for board members, specifically independent directors. Therefore, it fits best under Governance Information (CGR). The document length is 1792 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2023-11-10 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.